Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.40 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.40 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.40 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15487116 | 0.75 | MAPT (0.54) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL917373 | 0.73 | KMT2A (0.54) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL10351037 | 0.71 | ALOX15 (0.53) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL11758944 | 0.71 | KMT2A (0.51) | KMT2ASMN1; SMN2NPC1RAB9AALOX15 | |
| SCHEMBL10350257 | 0.71 | ALOX15 (0.53) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL10351038 | 0.71 | ALOX15 (0.53) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL10350256 | 0.71 | ALOX15 (0.53) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL15549028 | 0.71 | KMT2A (0.68) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL5696715 | 0.71 | KMT2A (0.68) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL5696854 | 0.71 | KMT2A (0.68) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | KMT2A 1770/4885SMN1; SMN2 3243/4885NPC1 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.